Price rise limit for non-scheduled drugs

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has revised the guidelines for non-scheduled drugs, and brought down the limit for annual price hikes from 20 per cent to 10 per cent.

The remaining criteria would be the same. The new rule applies to formulation packs with an annual turnover of over Rs 1 crore and for those that occupy more than 20 per cent of the market share, or are among the top three selling formulations in their segment. The price monitoring will continue to be on the basis of ORG IMS data, said the Authority in an official release. Non-compliance will call for action against the company. Further, the NPPA is reported to have upwardly revised the rates of 118 drugs by 12.46 per cent during the current fiscal and brought down the rates of 298 medicines by an average 31.46 per cent.